Related Experiment Video
Updated: Jul 4, 2025
Cholesterol Efflux Assay
Published on: March 6, 2012
Targeting cholesterol biosynthesis for AT/RT: comprehensive expression analysis and validation in newly established
Fumitaka Matsumoto1, Kiyotaka Yokogami2, Ai Yamada3
1Department of Neurosurgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. fumitaka_matsumoto@med.miyazaki-u.ac.jp.
Abstract:
Atypical teratoid/rhabdoid (AT/RT) is a rare and highly malignant tumor of the central nervous system (CNS). It is most commonly found in children less than 5 years of age and is associated with inactivation of loss of function of SMARCB1/INI1. An experimental model for AT/RT is necessary to develop new and effective therapies. We established a patient-derived new cell line (MZ611ATRT), which showed loss of BAF-47. MZ611ATRT genetically features somatic heterozygous deletion of SMARCB1 and single nucleotide deletion of the residual allele, exon 5 ([c.541delC]), resulting in a stop codon at codon 954 by frameshift. We assessed the RNA-sequencing data of the other two AT/RT cell lines with forced expression of SMARCB1 available from public databases. We found SMARCB1 overexpression significantly down-regulates the expression of a group of enzymes related to cholesterol biosynthesis. Simvastatin was highly sensitive against MZ611ATRT cells and induced apoptosis (IC50 was 3.098 µM for MZ611ATRT, 41.88uM for U-87 MG, 23.34uM for IOMM-Lee, and 18.12uM for U-251 MG.). Pathways involved in cholesterol biosynthesis may be new targets for adjuvant therapy of AT/RT.
Insights
A new patient-derived cell line models atypical teratoid/rhabdoid tumors (AT/RT). Simvastatin targeting cholesterol biosynthesis showed efficacy, suggesting a novel therapeutic avenue for this rare CNS cancer.
Area of Science:
- Neuro-oncology
- Molecular biology
- Cancer genetics
Background:
- Atypical teratoid/rhabdoid tumors (AT/RT) are aggressive central nervous system (CNS) cancers, primarily affecting young children.
- SMARCB1/INI1 gene inactivation is a hallmark of AT/RT, necessitating effective experimental models for therapeutic development.
Purpose of the Study:
- To establish a patient-derived cell line for AT/RT research.
- To investigate potential therapeutic targets by analyzing gene expression in AT/RT cells.
Main Methods:
- Established a new patient-derived AT/RT cell line (MZ611ATRT) with characterized SMARCB1 gene alterations.
- Performed RNA sequencing on AT/RT cell lines to assess gene expression profiles.
- Evaluated the sensitivity of MZ611ATRT cells to simvastatin, a cholesterol biosynthesis inhibitor.
Main Results:
- The MZ611ATRT cell line exhibited loss of BAF-47 and specific SMARCB1 mutations.
- SMARCB1 overexpression was found to down-regulate cholesterol biosynthesis enzymes.
- Simvastatin demonstrated significant cytotoxicity against MZ611ATRT cells (IC50 = 3.098 µM), inducing apoptosis.
Conclusions:
- Cholesterol biosynthesis pathways represent promising targets for novel adjuvant therapies in AT/RT.
- The MZ611ATRT cell line serves as a valuable preclinical model for AT/RT drug discovery.
